8-K: Avadel Board Deems Lundbeck Bid Superior to Alkermes Deal

Avadel Pharmaceuticals' Board of Directors has determined that an unsolicited acquisition proposal from H. Lundbeck A/S, valuing the company at up to $2.4 billion, constitutes a 'Company Superior Proposal' over its existing agreement with Alkermes plc.

Summary

• Avadel's Board declared Lundbeck's unsolicited proposal a "Company Superior Proposal" compared to the existing Alkermes transaction agreement.
• The Lundbeck Proposal offers up to $23.00 per ordinary share, totaling approximately $2.4 billion in equity value.
• This represents an approximate 29% premium to Avadel's closing price on October 21, 2025, the last business day prior to the announcement of the Alkermes acquisition.
• The offer includes $21.00 per share in cash at closing and a non-transferable Contingent Value Right (CVR) for potential additional cash payments of up to $2.00 per share.
• CVR payments are contingent on LUMRYZ and valiloxybate collectively reaching total annual net sales for end-use in the United States of at least $450 million by December 31, 2027, and at least $700 million by December 31, 2030.
• Avadel has notified Alkermes of this determination, triggering a five-business-day period for Alkermes to discuss or negotiate potential amendments to its transaction agreement.
• The Alkermes Transaction Agreement remains in full effect, and Avadel's Board has not yet changed its recommendation in support of the Alkermes acquisition.

Sentiment

Score: 8

Explanation: The filing indicates a significantly improved acquisition offer for Avadel shareholders, with a higher per-share value and a substantial premium. While there's a negotiation period and some uncertainty, the overall sentiment is highly positive due to the increased valuation and competitive interest in the company's assets.

Positives

• Lundbeck's proposal offers a higher valuation of up to $23.00 per share, representing a 29% premium over Avadel's share price as of October 21, 2025.
• The proposal includes a significant cash component of $21.00 per share at closing, providing immediate value to shareholders.
• Contingent Value Rights (CVRs) offer potential additional upside of up to $2.00 per share based on future sales performance of LUMRYZ and valiloxybate.
• The "Company Superior Proposal" designation indicates a potentially more favorable outcome for Avadel shareholders.

Negatives

• The CVR portion of the Lundbeck proposal is non-transferable, potentially limiting liquidity for shareholders who wish to exit their position entirely.
• The CVR payments are contingent on future sales targets ($450 million by 2027 and $700 million by 2030), introducing performance risk and uncertainty.
• The ongoing negotiation period with Alkermes creates uncertainty regarding the final acquisition partner and terms.
• There is no certainty that Lundbeck will make a firm offer or that any offer will be made on the stated terms.

Risks

• The ability of the parties to consummate the acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the consummation of the acquisition, including with respect to the approval of Avadel shareholders and required regulatory approvals.
• The potential impact of the unsolicited proposal from Lundbeck or the possibility that more competing offers may be made.
• Potential delays in consummating the acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the acquisition.
• The impact of health pandemics on the parties' respective businesses and the actions the parties may take in response thereto.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the transaction agreement.
• The effect of the announcement or pendency of the acquisition on Avadel's business relationships, operating results and business generally.
• Costs related to the acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition.
• The CVR payments are contingent on future sales targets for LUMRYZ and valiloxybate, which may not be met.

Future Outlook

Avadel's Board has determined Lundbeck's unsolicited proposal to be a "Company Superior Proposal" to the existing Alkermes agreement. This triggers a five-business-day period for Alkermes to potentially amend its offer. While the Alkermes agreement remains in effect and the Board's recommendation has not changed yet, there is a clear path for Avadel to potentially terminate the Alkermes agreement if Lundbeck's offer remains superior after Alkermes' response. The future outlook is uncertain regarding the final acquirer but points towards a potentially higher acquisition price for Avadel shareholders.

Management Comments

• Avadel's Board of Directors has determined in good faith, after consultation with its financial and legal advisors, that the unsolicited proposal that Avadel received from Lundbeck to acquire Avadel on November 13, 2025 (the Lundbeck Proposal), constitutes a Company Superior Proposal as defined in Avadel's existing transaction agreement with Alkermes plc.
• At this time, the Alkermes Transaction Agreement remains in full effect, and Avadel's Board has not changed its recommendation in support of the Alkermes acquisition.
• No action by Avadel shareholders is required at this time.
• Avadel will have no further comment on the Lundbeck Proposal or potential discussions with Alkermes until the Board has completed discussions and/or negotiations with Alkermes during the matching period pursuant to the terms of the Alkermes Transaction Agreement.

Industry Context

This announcement highlights the competitive landscape in the biopharmaceutical sector, particularly for companies with approved and promising products like Avadel's LUMRYZ. The unsolicited bid from Lundbeck, a major global pharmaceutical company, for Avadel, which already had an agreement with Alkermes, underscores the strategic value placed on specialized therapeutic assets and market access. The use of CVRs in the Lundbeck proposal is a common mechanism in biotech M&A to bridge valuation gaps and share future product success risks/rewards, especially for assets with significant but unproven commercial potential. The bidding war scenario suggests strong interest in Avadel's narcolepsy treatment, LUMRYZ, and potentially valiloxybate, indicating a robust market for sleep disorder therapeutics.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) in the Lundbeck proposal is a common practice in biopharmaceutical acquisitions, particularly when there is uncertainty around the future commercial success of pipeline or recently launched products. For example, Sanofi's acquisition of Principia Biopharma in 2020 included CVRs tied to the approval of tolebrutinib.
• The 29% premium offered by Lundbeck over Avadel's pre-announcement price is within the typical range for M&A premiums in the pharmaceutical industry, which often sees premiums from 20% to 50% depending on the strategic value and competitive bidding. For instance, Pfizer's acquisition of Arena Pharmaceuticals in 2021 offered a premium of over 100%, while some smaller deals might see lower premiums.
• The competitive bidding scenario, with Lundbeck challenging an existing agreement with Alkermes, is not uncommon in the biotech space, reflecting intense competition for valuable assets. A similar situation occurred with Shire and Baxalta, where Shire ultimately prevailed after a prolonged bidding process.
• The sales targets for LUMRYZ and valiloxybate ($450 million by 2027 and $700 million by 2030) are specific to Avadel's product portfolio and market potential within the narcolepsy treatment space. Comparing these directly to other companies' product sales targets would require detailed market analysis of specific drug classes and patient populations, which is beyond the scope of this filing.

Legal Proceedings

• The filing mentions the risk of "the outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the acquisition."

Stakeholder Impact

• Shareholders: Potential for a higher acquisition price and a significant premium, offering increased value for their holdings. However, the CVRs introduce contingent value and are non-transferable, which might affect some shareholders' liquidity preferences.
• Employees: The outcome of the acquisition (Alkermes or Lundbeck) could lead to changes in management, organizational structure, and potentially job roles, though no specifics are mentioned.
• Customers: No direct impact mentioned, but a change in ownership could influence future product development, marketing, and support for LUMRYZ.
• Creditors: No specific impact mentioned, but a change in ownership typically involves a review of existing debt agreements and potential refinancing.
• Suppliers: No specific impact mentioned, but a new owner might review supply chain relationships and contracts.

Next Steps

• Avadel will engage in discussions or negotiations with Alkermes for a five-business-day period if requested by Alkermes, regarding potential amendments to the Alkermes Transaction Agreement.
• Following this period, Avadel's Board will determine if the Lundbeck Proposal continues to be a "Company Superior Proposal" and if terminating the Alkermes agreement is consistent with fiduciary duties.
• Lundbeck must, by the seventh day prior to the date of the general meeting of Avadel shareholders convened to consider and approve the proposed scheme of arrangement to effect the proposed acquisition by Alkermes, either announce a firm intention to make an offer for Avadel or announce that it does not intend to make such an offer.
• Avadel intends to file a definitive proxy statement (which will include the scheme document) with the SEC.
• Avadel shareholders will eventually need to vote on the approved acquisition.

Key Dates

Recommendation

The announcement of a "Company Superior Proposal" from Lundbeck, offering up to $23.00 per share and a 29% premium, significantly increases the potential value for Avadel shareholders. While the Alkermes agreement is still in effect and a matching period is underway, the competitive bid signals strong interest and a likely higher acquisition price than initially anticipated. The CVRs offer additional upside potential tied to product performance. This situation strongly suggests that the stock price will appreciate, making it a strong buy for investors seeking to capitalize on the increased acquisition value.

Keywords

Avadel Pharmaceuticals, AVDL, Lundbeck, Alkermes, Acquisition, Takeover, Merger, Biopharmaceutical, LUMRYZ, Narcolepsy, Contingent Value Right, CVR, Superior Proposal